| NASDAQ (usa) |
|
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
| DAX (german) |
|
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Autolus Therapeutics plc (NASDAQ: AUTL)
AUTL Technical Analysis
5
| As on 25th Nov 2025 AUTL STOCK Price closed @ 1.39 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.92 & Strong Sell for SHORT-TERM with Stoploss of 2.38 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AUTLSTOCK Price
| Open | 1.35 | Change | Price | % |
| High | 1.49 | 1 Day | 0.15 | 12.10 |
| Low | 1.31 | 1 Week | 0.02 | 1.46 |
| Close | 1.39 | 1 Month | -0.23 | -14.20 |
| Volume | 32191094 | 1 Year | -1.93 | -58.13 |
| 52 Week High 3.32 | 52 Week Low 1.14 | ||||
NASDAQ USA Most Active Stocks
| LPTX | 2.05 | 365.91% |
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| NVDA | 177.82 | -2.59% |
| OPEN | 7.74 | 0.65% |
| LMDX | 0.02 | 0.00% |
| ONDS | 8.44 | -3.21% |
| AKTS | 0.04 | 0.00% |
| GOOGL | 323.44 | 1.53% |
| PLUG | 1.95 | -0.51% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AUTL Daily Charts |
AUTL Intraday Charts |
Whats New @ Bazaartrend |
AUTL Free Analysis |
|
|
AUTL Important Levels Intraday
| RESISTANCE | 1.74 |
| RESISTANCE | 1.63 |
| RESISTANCE | 1.56 |
| RESISTANCE | 1.49 |
| SUPPORT | 1.29 |
| SUPPORT | 1.22 |
| SUPPORT | 1.15 |
| SUPPORT | 1.04 |
AUTL Forecast November 2025
| 4th UP Forecast | 2.97 |
| 3rd UP Forecast | 2.46 |
| 2nd UP Forecast | 2.15 |
| 1st UP Forecast | 1.84 |
| 1st DOWN Forecast | 0.94 |
| 2nd DOWN Forecast | 0.63 |
| 3rd DOWN Forecast | 0.32 |
| 4th DOWN Forecast | -0.19 |
AUTL Weekly Forecast
| 4th UP Forecast | 2.33 |
| 3rd UP Forecast | 2.03 |
| 2nd UP Forecast | 1.84 |
| 1st UP Forecast | 1.66 |
| 1st DOWN Forecast | 1.12 |
| 2nd DOWN Forecast | 0.94 |
| 3rd DOWN Forecast | 0.75 |
| 4th DOWN Forecast | 0.45 |
AUTL Forecast2025
| 4th UP Forecast | 5.92 |
| 3rd UP Forecast | 4.47 |
| 2nd UP Forecast | 3.57 |
| 1st UP Forecast | 2.67 |
| 1st DOWN Forecast | 0.11 |
| 2nd DOWN Forecast | -0.79 |
| 3rd DOWN Forecast | -1.69 |
| 4th DOWN Forecast | -3.14 |
Autolus Therapeutics plc ( NASDAQ USA Symbol : AUTL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AUTL Other Details
| Segment | EQ | |
| Market Capital | 408085984.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
AUTL Address
![]() |
||
AUTL Latest News
AUTL Business Profile
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. Address: Forest House, London, United Kingdom, W12 7RZ
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

